CERUS CORP
CERS · XNASCIK 1020214fmd_0595GGBGBJK080KQM6PWDD2WA9Manufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 39 | 51 | 76 | 94 | 114 | 160 | 188 | 187 | 201 | 234 |
| Cost of revenue | 20 | 23 | 32 | 33 | 41 | – | – | – | – | – |
| Gross profit | 17 | 29 | 44 | 60 | 73 | – | – | – | – | – |
| Research and development | 31 | 34 | 43 | 60 | 64 | 64 | 64 | 68 | 59 | 68 |
| Selling, general and administrative | 49 | 53 | 57 | 66 | 67 | 81 | 83 | 76 | 76 | 81 |
| Total operating expenses | 80 | 86 | 99 | 127 | 131 | 145 | 147 | 147 | 135 | 149 |
| Operating income | (61) | (58) | (55) | (66) | (58) | (49) | (34) | (30) | (14) | (9) |
| Interest expense | 2 | 3 | 4 | 6 | 4 | 5 | 6 | 8 | 9 | 8 |
| Other non-operating income (expense) | (1) | 1 | (2) | (5) | (1) | (5) | (8) | (7) | (7) | (7) |
| Income before taxes | (63) | (57) | (57) | (71) | (60) | (54) | (42) | (37) | (21) | (15) |
| Income tax expense | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (63) | (61) | (58) | (71) | (60) | (54) | (43) | (38) | (21) | (16) |
| Net income | (63) | (61) | (58) | (71) | (60) | (54) | (43) | (37) | (21) | (16) |
| Net income to common shareholders | (63) | (61) | – | – | – | – | – | – | – | – |